This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutHow Cibinqo worksIntroducing CibinqoEfficacyEfficacyClinical EfficacyStudy OverviewJADE DAREJADE COMPAREJADE MONOJADE REGIMENJADE TEENJADE EXTENDSafety
Safety
 
Safety
 
Safety GuidanceDosingDosingDosingStarting your patients on CibinqoPractical considerationsValueSupport & ResourcesSupport & ResourcesPatient ResourcesVideos
Materials

Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.
Updated Safety Recommendation - Abrocitinib should only be used if no suitable treatment alternatives are available in patients: 65 years of age and older, patients with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), patients with malignancy risk factors (e.g. current malignancy or a history of malignancy). (Cibinqo Summary of Product Characteristics)


Safety guidance: Summary of the safety profile of Cibinqo

Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.1

Cibinqo is contraindicated in patients with1:

• Hypersensitivity to the active substance or to any of the excipients.​

• Active serious systemic infections, including tuberculosis​

• Severe hepatic impairment ​

• Pregnancy and breast-feeding 

Cibinqo should only be used if no suitable treatment alternatives are available in patients 1:

  • 65 years of age and older;​

  • patients with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers);​

  • patients with malignancy risk factors (e.g. current malignancy or a history of malignancy)

Use in patients 65 years of age and older1:

Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients 65 years of age and older, as observed in a large randomised study of another JAK inhibitor, Cibinqo should only be used in these patients if no suitable treatment alternatives are available.

Safety profile of Cibinqo: Tabulated list of adverse reactions1

A total of 3,848 patients were treated with Cibinqo in clinical studies in atopic dermatitis, among them 3,050 patients (representing 5,166 patient-years of exposure) were integrated for safety analysis, 2,013 with at least 48 weeks of exposure. The integrated safety analysis included 1,997 patients receiving a constant dose of abrocitinib 200 mg and 1,053 patients receiving a constant dose of 100 mg. Five placebo‑controlled studies were integrated (703 patients on 100 mg once daily, 684 patients on 200 mg once daily and 438 patients on placebo) to evaluate the safety of Cibinqo in comparison to placebo for up to 16 weeks.1

A total of 635 adolescents (12 to less than 18 years of age) were enrolled in Cibinqo atopic dermatitis studies representing 1326.1 patient-years of exposure. The safety profile observed in adolescents in atopic dermatitis clinical studies was similar to that of the adult population.1

The most commonly reported adverse reactions occurring in ≥2% of patients treated with Cibinqo 200 mg in placebo-controlled studies are nausea (15.1%), headache (7.9%), acne (4.8%), herpes simplex (4.2%), blood creatine phosphokinase increased (3.8%), vomiting (3.5%), dizziness (3.4%) and abdominal pain upper (2.2%). The most frequent serious adverse reactions are infections (0.3%).1


PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION

Scroll left to view table
System organ class Very common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1/1000 to <1/100)
Infections and infestations   Herpes simplex,a Herpes zosterb Pneumonia
Blood and lymphatic system disorders     Thrombocytopenia, Lymphopenia
Metabolism and nutrition disorders     Hyperlipidaemiac
Nervous system disorders   Headache, Dizziness  
Vascular disorders     Venous thromboembolismd
Gastrointestinal disorders Nausea Vomiting, Abdominal pain upper  
Skin and subcutaneous tissue disorders   Acne  
Investigations   Creatine phosphokinase increased >5 x ULNe  

Adapted from Cibinqo (abrocitinib) Summary of Product Characteristics.


a. Herpes simplex includes oral herpes, ophthalmic herpes simplex, genital herpes and herpes dermatitis.

b. Herpes zoster includes ophthalmic herpes zoster.

c. Hyperlipidaemia includes dyslipidaemia and hypercholesterolaemia.

d. Venous thromboembolism includes pulmonary embolism and deep vein thrombosis.

e. Includes changes detected during laboratory monitoring.

PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION​​​​​​​.
Scroll left to view table
Scroll left to view table
Scroll left to view table
Description of selected adverse reactions with Cibinqo1

FOR FURTHER INFORMATION ON ADVERSE REACTIONS PLEASE SEE THE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS 

Infections1
Scroll left to view table
Infections/Serious infections1
In placebo-controlled studies, for up to 16 weeks, infections have been reported in 27.4% of patients treated with placebo and in 34.9% and 34.8% of patients treated with Cibinqo 100 mg and 200 mg, respectively. Most infections were mild or moderate.

The percentage of patients reporting infection-related adverse drug reactions in the 200 mg and 100 mg groups compared to placebo were: herpes simplex (4.2% and 2.8% versus 1.4%), herpes zoster (1.2% and 0.6% versus 0%), pneumonia (0.1% and 0.1% versus 0%). Herpes simplex was more frequent in patients with a history of herpes simplex or eczema herpectium. Most of the herpes zoster events involved a single dermatome and were non-serious.

Among all patients treated in clinical studies with consistent dosing regimens of either Cibinqo 100 mg or 200 mg, including the long-term extension study, the incidence rate of herpes zoster in patients treated with abrocitinib 200 mg (4.36 per 100 patient-years) was higher than that of patients treated with 100 mg (2.61 per 100 patient-years). Incidence rates for herpes zoster were also higher for patients 65 years of age and older (HR 1.76), patients with a medical history of herpes zoster (HR 3.41), patients with severe atopic dermatitis at baseline (HR 1.17), and a confirmed ALC < 1.0 × 103/mm3 prior to the event of herpes zoster (HR 2.18).

In placebo‑controlled studies, for up to 16 weeks, the rate of serious infections was 1.81 per 100 patient-years in patients treated with placebo, 3.32 per 100 patient-years in patients treated with 100 mg, and 1.12 per 100 patient-years in patients treated with 200 mg.

Among all patients treated in clinical studies with consistent dosing regimens of either Cibinqo 100 mg or 200 mg, including the long-term extension study, the rate of serious infections was 2.20 per 100 patient-years treated with 100 mg and 2.48 per 100 patient-years treated with 200 mg. The most commonly reported serious infections were herpes simplex, herpes zoster, and pneumonia. 
Opportunistic infections were observed. Most of these were cases of herpes zoster (0.70 per 100 patient-years in the abrocitinib 100 mg group and 0.96 per 100 patient-years in the abrocitinib 200 mg group) and were non-serious multidermatomal cutaneous infections. Tuberculosis was observed in the abrocitinib 200 mg group (0.06 per 100 patient-years).PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION.Venous thromboembolism1
Scroll left to view table

Among all patients treated in clinical studies with consistent dosing regimen of either Cibinqo 100 mg or 200 mg, including the long‑term extension study, the rate of PE was 0.05 per 100 patient-years for 100 mg group and 0.21 per 100 patient-years for 200 mg group. The rate of DVT was 0.05 per 100 patient-years in the Cibinqo 100 mg group and 0.06 per 100 patient‑years in the Cibinqo 200 mg group.
PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION.Nausea1
Scroll left to view table
In placebo-controlled studies, for up to 16 weeks, nausea was reported in 1.8% of patients treated with placebo and in 6.3% and 15.1% of patients treated with 100 mg and 200 mg, respectively. Discontinuation due to nausea occurred in 0.4% of patients treated with Cibinqo. Among patients with nausea, 63.5% of patients had onset of nausea in the first week of therapy. The median duration of nausea was 15 days. Most of the cases were mild to moderate in severity.1
PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION.Acne1
Scroll left to view table
In placebo-controlled studies, for up to 16 weeks, acne was reported in 0.2% of patients treated with placebo and in 1.8% and 4.8% of patients treated with 100 mg and 200 mg, respectively. No subjects discontinued due to an event of acne. All events were mild to moderate in severity.1
PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION.Laboratory abnormalities in patients taking Cibinqo in placebo-controlled studies1Thrombocytopenia1In placebo‑controlled studies, for up to 16 weeks, treatment was associated with a dose‑related decrease in platelet count. Maximum effects on platelets were observed within 4 weeks, after which the platelet count returned towards baseline despite continued therapy. Confirmed platelet counts of <50 × 103/mm3 were reported in 0.1% of patients treated with 200 mg, and in 0 patients treated with 100 mg or placebo.
Among all patients treated in clinical studies with consistent dosing regimens of either Cibinqo 100 mg or 200 mg, including the long‑term extension study, the rate of confirmed platelet counts of <50 × 103/mm3 was 0.15 per 100 patient-years for 200 mg and 0 per 100 patient-years for 100 mg, most occurring at Week 4. Patients 65 years of age and older had a higher rate of platelet counts <75 × 103/mm3PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION.Lymphopenia1In placebo‑controlled studies, for up to 16 weeks, confirmed ALC <0.5 × 103/mm3 occurred in 0.3% of patients treated with 200 mg and 0% of patients treated with 100 mg or placebo. Both cases occurred in the first 4 weeks of exposure.

Among all patients treated in clinical studies with consistent dosing regimens of either Cibinqo 100 mg or 200 mg, including the long‑term extension, the rate of confirmed ALC <0.5 × 103/mm3 was 0.34 per 100 patient-years for 200 mg and 0.05 per 100 patient-years for 100 mg, the highest rate was observed in patients 65 years of age and older. There were no adolescent patients who developed an ALC <0.5 × 103/mm3.PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION.Lipid Elevations1

In placebo-controlled studies, for up to 16 weeks, there was a dose-related increase in low-density lipoprotein cholesterol (LDL-c), total cholesterol, and high-density lipoprotein cholesterol
(HDL-c) relative to placebo at Week 4 which remained elevated through the final visit in the treatment period.1

The median% change in LDL-c at Week 4 was 9.1%, 4.9% and -2.8% in patients exposed to 200 mg, 100 mg and placebo, respectively; at Month 12 the median % change was 22.8% and 13.7% in the 200 mg and 100 mg groups, respectively. The median % change in HDL-c at Week 4 was 20.0%, 12.1%, and 0% in patients exposed to 200 mg, 100 mg and placebo, respectively; at Month 12 the median% change was 17.1% and 8.9% in the 200 mg and 100 mg groups, respectively.1

Events related to hyperlipidaemia occurred in 0.4% of patients exposed to Cibinqo 100 mg, 0.6% of patients exposed to 200 mg and 0% of patients exposed to placebo.1PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION.Creatine phosphokinase elevations1In placebo-controlled studies, for up to 16 weeks, significant increases in CPK values (>5 × ULN) occurred in 1.8% of patients treated with placebo, 1.8% of patients treated with 100 mg and 3.8% of patients treated with 200 mg of Cibinqo, respectively. Most elevations were transient, and none led to discontinuation.1PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION.

For information about monitoring patients on Cibinqo, please visit the Practical Considerations page below:

Practical Considerations | Cibinqo®▼ (abrocitinib) | PfizerPro UK

Explore moreStarting your patients on Cibinqo

Learn more about flexible dosing in patients on Cibinqo.

Discover oral once-daily dosingLoading
Practical considerations

Learn more about monitoring patients on Cibinqo.

View requirementsLoading

AE=adverse event; ALC=absolute lymphocyte count; CI=confidence interval; CPK=creatine phosphokinase; DVT=deep vein thrombosis; HDL-c=high-density lipoprotein cholesterol; IR=incidence rate; LDL-c=low-density lipoprotein cholesterol; MACE=major adverse cardiovascular events; NMSC=non-melanoma skin cancer; PE=pulmonary embolism; PY=patient years; ULN=upper limit of normal.

Prescribing information:
Cibinqo (abrocitinib) Prescribing information 

References:

Cibinqo (abrocitinib) Summary of Product Characteristics.
PP-CIB-GBR-1840. April 2025

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc/product/12874/rmms. Patients treated with Cibinqo should be given the Patient Card.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2025 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-11245. January 2025
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024.

YesNo
You are now leaving PfizerPro​​​​​
​
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-GBR-12070. April 2025​​​​​​​
​​​​​​​
You are now leaving PfizerPro

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

PP-UNP-GBR-12107. April 2025
​​​​​​​